At close: 3:29:59 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
44,444,000.00
44,901,600.00
44,963,380.00
37,271,720.00
31,960,346.00
Cost of Revenue
19,231,340.00
21,257,940.00
23,833,620.00
19,589,020.00
14,550,046.00
Gross Profit
25,212,660.00
23,643,660.00
21,129,760.00
17,682,700.00
17,410,300.00
Operating Expense
17,568,420.00
17,091,040.00
13,752,790.00
11,933,720.00
10,254,788.00
Operating Income
7,644,240.00
6,552,620.00
7,376,970.00
5,748,980.00
7,155,512.00
Net Non Operating Interest Income Expense
-1,072,960.00
-1,030,240.00
-514,190.00
-103,580.00
-139,054.00
Pretax Income
6,555,600.00
5,472,290.00
6,871,730.00
5,580,010.00
7,043,643.00
Tax Provision
1,683,790.00
1,419,190.00
1,705,760.00
1,452,400.00
1,549,053.00
Net Income Common Stockholders
4,871,810.00
4,053,100.00
5,165,970.00
4,127,610.00
5,494,590.00
Diluted NI Available to Com Stockholders
4,871,810.00
4,053,100.00
5,165,970.00
4,127,610.00
5,494,590.00
Basic EPS
20.10
16.73
21.05
16.66
22.05
Diluted EPS
20.09
16.72
21.00
16.60
21.95
Basic Average Shares
242,383.86
242,210.00
245,410.00
247,840.00
249,203.00
Diluted Average Shares
242,455.15
242,350.00
245,740.00
248,610.00
250,278.00
Rent Expense Supplemental
--
219,800.00
111,610.00
79,670.00
78,251.00
Total Expenses
36,799,760.00
38,348,980.00
37,586,410.00
31,522,740.00
24,804,834.00
Net Income from Continuing & Discontinued Operation
4,871,810.00
4,053,100.00
5,165,970.00
4,127,610.00
5,494,590.00
Normalized Income
4,907,154.33
4,088,327.69
5,176,683.15
4,162,997.90
5,522,547.21
Interest Income
--
27,970.00
45,140.00
128,540.00
123,787.00
Interest Expense
760,310.00
717,590.00
354,230.00
118,400.00
196,179.00
Net Interest Income
-1,072,960.00
-1,030,240.00
-514,190.00
-103,580.00
-139,054.00
EBIT
7,315,910.00
6,189,880.00
7,225,960.00
5,698,410.00
7,239,822.00
EBITDA
9,425,520.00
8,263,200.00
9,070,900.00
7,284,730.00
8,754,447.00
Reconciled Cost of Revenue
19,231,340.00
21,257,940.00
23,833,620.00
19,589,020.00
14,550,046.00
Reconciled Depreciation
2,109,610.00
2,073,320.00
1,844,940.00
1,586,320.00
1,514,625.00
Net Income from Continuing Operation Net Minority Interest
4,871,810.00
4,053,100.00
5,165,970.00
4,127,610.00
5,494,590.00
Total Unusual Items Excluding Goodwill
-47,560.00
-47,560.00
-14,250.00
-47,840.00
-35,839.00
Total Unusual Items
-47,560.00
-47,560.00
-14,250.00
-47,840.00
-35,839.00
Normalized EBITDA
9,473,080.00
8,310,760.00
9,085,150.00
7,332,570.00
8,790,286.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-12,215.67
-12,332.31
-3,536.85
-12,452.10
-7,881.79
3/31/2021 - 6/20/2005
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
LAURUSLABS.NS Laurus Labs Limited
563.80
-1.56%
DRREDDY.NS Dr. Reddy's Laboratories Limited
1,245.40
+0.55%
IOLCP.NS IOL Chemicals and Pharmaceuticals Limited
417.75
+3.69%
SEQUENT.NS Sequent Scientific Limited
184.44
-2.53%
AARTIDRUGS.NS Aarti Drugs Limited
446.30
-1.65%
MOREPENLAB.NS Morepen Laboratories Limited
88.35
-0.14%
IPCALAB.NS Ipca Laboratories Limited
1,560.50
+0.53%
INNOVACAP.NS Innova Captab Limited
1,041.45
-2.76%
PPLPHARMA.NS Piramal Pharma Limited
251.80
-2.54%
ERIS.NS Eris Lifesciences Limited
1,512.90
-0.64%